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Post embolization syndromeAbstract Purpose: To assess the efﬁcacy of intra-arterial Lidocaine on post-procedural pain and on
length of hospital stay in hepatocellular carcinoma (HCC) patients undergoing chemoembolization.
Materials and methods: Thirty-nine transarterial chemoembolization (TACE) procedures were car-
ried out for 21 consecutive patients (19M, 2F, age range 52–78).This is a prospective randomized con-
trolled study. Lidocaine was used in 20 TACE and normal saline in 19 TACE. Visual analog scoring
was used to assess pain (VAS).
Results: Patients’ demographic criteria, Child Pugh, tumor size and doses of chemotherapeutic emul-
sion and amount of usedPVparticles were not statistically signiﬁcantly different between both groups.
Average periprocedure VAS was 3.2 versus 7.4 for Lidocaine and Placebo groups, respectively
(p= 0.0001). Postprocedure VAS in the Lidocaine group was 4.1 ± 1.6 and that for the Placebo
group was 6.1 ± 1.3 (P= 0.001). Mean daily dose of Nalbuphine in the Lidocaine group was 8 mg
versus 18 for patients in the Placebo group (p= 0.002).Average length of post procedure hospital stay
was 3.7 and 3.8 days for Lidocaine and Placebo groups, respectively (P= 0.36).
Conclusions: Intra-arterial administration of buffered Lidocaine before infusing the embolization
particle of TACE is safe and effective in dose as low as 50 mg for reducing peri and post-procedural
pain and dosage of narcotic analgesics in patients with HCC.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Transarterial chemoembolization (TACE) is a well known
technique for the management of unresectable hepatocellular
carcinoma. TACE may be used as a neoadjuvant and bridging
to resection or orthotopic liver transplantation (1). It is
indicated as a palliative treatment and considered as the ﬁrst
404 M.A. Abusedera et al.line therapy for intermediate stage HCC according to the rec-
ommendation of American Association for study of liver dis-
eases based on randomized controlled trials (2,3).
TACE is simply administration of cytotoxic drugs, with or
without lipiodol, by means of a catheter directly to the hepatic
artery followed by the administration of embolizing agents
such as spherical gelatin or polyvinyl alcohol particles (4).
Postembolization syndrome (PES) is a common complica-
tion after embolic procedures, and it is a frequent cause of ex-
tended inpatient hospital admissions. PES is a self-limited
constellation of symptoms consists of fevers, unremitting nau-
sea, general malaise, loss of appetite, and variable abdominal
pain following the procedure. Although a deﬁnite cause is un-
known, this syndrome is thought to be a result of therapeutic
cytotoxicity, tumor ischemia, and resulting intrahepatic and
extrahepatic inﬂammation (5).
Intraarterial Lidocaine administration during TACE has
been known not only for reduction of severity of the pain that
is associated with TACE but facilitates faster recovery as well
(6,7).
Lee et al. found that: transcatheter administration of Lido-
caine immediately before infusion of chemotherapy had signif-
icantly better effect on pain control than after chemotherapy
emulsion (8).
1.1. Purpose
To assess the efﬁcacy of intra-arterial buffered Lidocaine
on post-procedural pain and on length of hospital stay in
hepatocellular carcinoma (HCC) patients undergoing
chemoembolization.
2. Materials and methods
Institutional ethics committee approved this prospective ran-
domized controlled study. Informed consent was obtained
from the entire patients prior to the procedure.
All patients were subjected to thorough evaluation. HCC
was diagnosed in all patients either by results of histopathol-
ogical exam or typical imaging criteria of HCC with triphasic
dynamic contrast study by CT or MRI in addition to High
serum level of Alfa fetoprotein that is more than 400 ngm/
ml. Other laboratory investigations were ordered including:
Liver and renal function tests, CBC to evaluate platelets
count, Prothrombine time, concentration and INR. Exclu-
sion criteria were; uncorrected coagulopathy, Inﬁltrative type
of HCC, tumor volume more than 50% of the liver, patients
with Child C according to Child Pugh classiﬁcation, extra
hepatic liver metastasis of HCC that was conﬁrmed by CT
chest, abdomen and pelvis and thrombosis of main portal
vein.
Conscious sedation was not provided to any of our patents.
Continuous monitoring of blood pressure, pulse and cardiac
electricity was provided during the entire procedure. TACE
was performed after visceral angiography to evaluate arterial
supply of the HCC and evaluate patency of portal vein.
HCC arterial supply was accessed by selective segmental using
standard 5 Fr catheter or 3 Fr coaxial technique using Rene-
gade Hiﬂow microcatheter (Boston Scientiﬁc USA). Having
the catheter in good position emulsion of Doxorubicin 50 mg
and 50 mg Cisplatinum and 10 mg of Mitomycin C was mixedwith 10 ml of water soluble contrast Urograﬁn 76% (SCHER-
ING-Germany) and 10 ml lipiodol (ultra-ﬂuids Guerbet
France). The total volume of the chemotherapeutic emulsion
was about 22 ml. The chemotherapeutic emulsion was infused
under ﬂuoroscopy guidance till good staining of HCC was
seen. The infused volume of chemotherapeutic emulsion was
estimated. Five to 10 ml of buffered Lidocaine 2% was infused
in patients assigned to the Lidocaine group just before of infu-
sion of PV particles and saline was infused in patients assigned
to the Placebo group. Buffered Lidocaine was prepared by
adding 2 ml of Sodium Bicarbonate 8.4% to 20 ml of
Lidocaine 2% for a ﬁnal volume of 22. In both groups, the
procedure was concluded by infusing aliquots of polyvinyl
alcohol particle (PVA) size of 150–250 micron. The volume
of the infused chemotherapeutic emulsion and volume of
PVA vial were calculated in both groups.
Good hydration was assured for entire patients before and
after procedure by IV normal saline infusion till the ability to
drink. Pain was recorded using visual analog score (VAS) con-
sidering 1 is minimal discomfort and 10 is the severest pain.
Pain scores were recorded 4 times per day. Pain score of 5 or
more was considered as signiﬁcant pain that required analge-
sia. Post procedure analgesia was provided by Nalbuphine
IV and daily doses and total doses were recorded for each pa-
tient. Body temperature and hospital stay all were recorded for
each patient in both groups. The mean dose of Nalbuphine per
day and total doses were calculated for each patient. Mean of
the VAS scores between the 2 groups was compared. Ondanse-
tron hydrochloride (Zofran), 4 mg slowly IV infusion was of-
fered to patients who had nausea.
Non contrast axial CT for the abdomen was obtained with-
in the ﬁrst week. Evaluation of serum Bilirubin, Albumin, Pro-
thrombin time, conc., INR and ALT and AST was done
within the ﬁrst week of TACE and repeated after 6 weeks. Ser-
um Alfa fetoprotein was evaluated 6 weeks after TACE only
for patient who had high base line Alfa fetoprotein in addition
to triphasic dynamic MRI after 6 weeks.
Statistical analyses were performed with the chi-square test
and ANOVA with multiple comparisons using SPSS. P value
less than 0.05 was considered signiﬁcant.3. Results
Thirty-nine transarterial chemoembolization (TACE) proce-
dures were carried out for 21 consecutive patients (19M, 2F,
age range 52–78). This is a prospective randomized controlled
study; Lidocaine Group consisted of 20 TACE procedures in
10 patients at rate of 2 sessions per patient who received in-
tra-arterial buffered Lidocaine during chemoembolization.
Placebo group consists of 19 procedures in 11 patients at rate
of 1.7 procedures per patient in whom Lidocaine was substi-
tuted with normal saline solution.
The patient demographic criteria, Child Pugh, tumor size
and doses of chemotherapeutic emulsion and amount of PV
particles used were comparable without statistically signiﬁcant
difference Table 1.
TACE technique was super selective or segmental for both
Lidocaine and Placebo groups (Fig. 1). Three patients out of
21 patients had bilobar involvement. Each lobe was treated
separately at different session. The majority of patients
had right lobe lesions. Four TACE procedures were carried
Fig. 1 62 year man who has single HCC at the right lobe,
superselective segmental right hepatic angiogram showing hyper
vascular HCC.
Fig. 2 62 year man who has single HCC at the right lobe. Non-
contrast axial CT scan for upper abdomen 3 days after TACE
showing intense uptake of the chemotherapeutic emulsion by
HCC. He is same patient as mentioned in Fig. 1.
Efﬁcacy of intra-arterial Lidocaine 405out for left lobe lesions in 2 patients. There was no recorded
inadvertent embolization of the gall bladder.
Good uptake of the chemotherapeutic emulsion was con-
ﬁrmed by CT scan (Fig. 2).
Classic anatomy of the celiac trunk was noticed in 20 pa-
tients and a single patient showed replaced right hepatic artery
originated from the superior mesenteric artery Fig. 3.
There were no vascular complications during TACE proce-
dure such as dissection or spasm of hepatic artery.
The infused dose of chemotherapeutic emulsion till tumor
bed saturation ranged from 0.5 to 0.9 of the prepared chemo-
therapeutic emulsion for the Lidocaine group and from 0.5 to
0.8 of the emulsion in the Placebo group and the dose differ-
ence was not statistically signiﬁcant and so did the volume of
the embolization particles, PVA.
There were no recorded changes in blood pressure or
arrhythmias in patients who received buffered Lidocaine.
Mild inter procedure pain was noticed in 65% of the Lido-
caine group (n= 13) with VAS of 3 in the Lidocaine group
compared to 42% in the Placebo group (n= 8).
No pain during TACE was encountered in 35% (n= 7) of
the Lidocaine group; 5 of them had TACE twice, compared to
5% in the Placebo group (n= 1).
The average periprocedure pain score was less in the Lido-
caine group than in the Placebo group. The average VAS was
3.2 versus 7.4 for both Lidocaine and Placebo groups respec-
tively (p= 0.0001) (Table 2). Post procedure pain was signiﬁ-
cantly lower in Lidocaine group versus Placebo group. VAS
for pain in the Lidocaine group was 4.1 ± 1.6 and that for
the Placebo group was 6.1 ± 1.3, the difference is signiﬁcant
(P= 0.001). The frequency of analgesic demands was higher
in patients who did not receive Lidocaine and mean daily dose
of Nalbuphine in the Lidocaine group was 8 mg versus 18 for
patients in the Placebo group (p= 0.002) (Table 2). It is inter-
esting to notice that VAS and doses of nalbuphine were not
statistically signiﬁcant in patients who received 50 mg or
75 mg or 100 mg of Lidocaine intra arterially (Table 3).
Nausea was encountered in 95% of patients belonging to
the Lidocaine group (n= 19) and it was 100% in those
belonging to the Placebo group. The elapsed time from begin-
ning of the procedure till the patient started to eat and drink
(time to eat and drink) was close in both groups .The average
duration for Lidocaine group was 15 h and ranged from 8 to
36 and that for patients in Placebo group was 13 h ranging
from 9 to 33 hours. Incidence of post procedure fever was
not statistically different in Lidocaine and Placebo groups.
4 mg of ondansetron hydrochloride (Zofran), was slowly of-
fered as iv infusion to patients in 95% of TACE procedures
in the Lidocaine group (n= 19) and repeated for more than
three days in 60% of procedures (n= 12). Zofran was offeredTable 1 Comparison between patients who received intra arterial L
Lidocaine group
Mean SD
Age in years 62.2 9.5
Child Pugh 6.3 0.9
Tumor size in cm 8.7 1.7
Chemotherapy dose 0.9 0.1
PV particles 0.8 0.2to the entire Placebo group patients and repeated more than
three days in 79% (n= 15).
The length of patient hospitalization after TACE ranged
from 15 h post procedure to 7 days for the Lidocaine group
and 14 h to 8 days for the Placebo group. The average length
of post procedure hospital stay was 3.7 and 3.8 days foridocaine versus who received Placebo.







Fig. 3 73 year old man with two focal HCC at the right lobe.
Superior mesenteric angiogram showed replaced right hepatic
artery originating from the superior mesenteric artery.
406 M.A. Abusedera et al.Lidocaine and Placebo groups respectively. That difference
was not statistically signiﬁcant (P= 0.36).
4. Discussion
Postembolization syndrome (PES) is experienced after 80–90%
of TACE procedures. It has widely variable manifestations but
often includes pain, fever, nausea, and vomiting. PES can last
from a few hours to a few days (1). Although it is a self-limit-
ing condition, it is a major complication of hepatic TACE
causing longer hospitalization (4). The large doses of intrave-
nous narcotics needed to control the pain leads to altered men-
tal status and respiratory depression; therefore, intensive
monitoring is required. Narcotics potentiate severe post embo-
lization nausea and vomiting (6). The exact explanation ofTable 2 Showed difference between Lidocaine and Placebo group
Lidocaine group
Mean SD
Inter procedure VAS 3.2 1.1
Daily dose of nalbuphine 8 6.2
Total doses of nalbuphine 28.8 7.0
Post procedure VAS 4.1 1.5
Postprocedure fever frequency 0.7
Length of hospital stay 3.7 1.8
VAS: visual analog scores.




* P value = .01.
 P value = .03.
1 P value = .02.pain component of PES in TACE is not known but many
hypotheses are postulated such as ischemia and transient swell-
ing of liver parenchyma that stretches the liver capsule or acci-
dental embolization of the gall bladder. Severe pain during the
procedure can be explained by irritant effect of the chemother-
apeutic emulsion on the hepatic artery branches (6,7).
Direct irritation of the arterial wall by the chemotherapeu-
tic emulsion is one of the theories of pain component of PES.
Daniel et al. found that: pain at TACE was lower after the ﬁrst
session and this could be explained by lower dose of chemo-
therapy in the successive TACE sessions than that of the ﬁrst
TACE session (9). In our study 5 out of 7 patients who had
no pain during the TACE were subjected to previous TACE
session. In superselective TACE, the arterial system which is
in contact with irritant chemotherapeutic emulsion is at mini-
mum and the dose is lower than lobar TACE technique and
carries less risk for non target embolization of the gall bladder.
Inadvertently embolized gall bladder was considered as one of
the theories of pain component of PES.
Contrary to Daniel et al., Patel et al. found that repetition
of TACE is not a predictor of pain component of PES as their
hypothesis was that: ischemic pain was the main mechanism
and vascular irritation by chemotherapeutic emulsion was
not the major cause for pain (10).
In a study by Coldwell et al. excellent analgesia during he-
patic TACE was achieved with a celiac plexus block. However
this method seems to be risky and time-consuming (11).
Lidocaine has been shown to help control the painful re-
sponse to the injection of iodinated contrast material in periph-
eral arteries (12,13).
Molgaard et al. (6) studied the use of intraarterial Lido-
caine in hepatic arterial branches prior to and during TACE.
This resulted in a signiﬁcant decrease in the amount of mor-
phine required during the procedure, as well as the need for
subsequent postprocedure morphine drip. It remains clear
that the sequelae of pain during and after TACE, such as
shallow respirations and paralytic ileus, can complicate patient
management.as regard pain.









*75 mg Lidocaine 100 mg Lidocaine,1
4.4 4.6
1.7 1.3
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mended because it is a much easier and less time-consuming
method than celiac plexus block.
The mechanism of the analgesic effect of intra-arterial
Lidocaine in hepatic TACE is unclear. Hartnell et al. (7), sug-
gested that Lidocaine has a direct local effect after diffusion
into the arterial wall and liver parenchyma, and this effect will
be prolonged in tumors where blood ﬂow is occluded, prevent-
ing washout of the agent.
Unbuffered Lidocaine (pH = 6.5) is commonly employed
as a local anesthetic prior to transcutaneous interventional
procedures. Lidocaine administration is associated with sting-
ing or burning pain at the injection site. The buffered anes-
thetic had a statistically signiﬁcant reduction in the pain
associated with inﬁltration of Lidocaine without any compro-
mise in its therapeutic efﬁcacy as observed on a linear visual
analog scale (14). Intraarterial administration of buffered
Lidocaine is less irritant to arteries and associated with less dis-
comfort than unbuffered Lidocaine.
Lee et al. found that: patients who had received Lidocaine
by intraarterial route during TACE procedure needed smaller
doses of narcotic analgesics than those who had not received
Lidocaine (8). These results are consistent with our results.
Different protocols for intraarterial Lidocaine administra-
tion were applied. Sharma et al. (15) used Lidocaine intermit-
tently during the procedure. Hartnell et al. (7) injected
Lidocaine at varying intervals before and during TACE up
to 4 times. The dose of Lidocaine used in their study (maxi-
mum 105 mg injected over 10–20 min) was safe and effective.
However Lee et al. (8) concluded that intraarterial administra-
tion of Lidocaine just before TACE was much useful than after
TACE as regards pain control and post procedure requirement
for narcotic.
In our study we used Lidocaine as bolus rather than infu-
sion; we found that 50 mg of buffered Lidocaine was effective
to alleviate pain during the procedure and reduced pain score
and analgesic dose after the procedure. In our study we used
buffered Lidocaine which may explain good control of pain
during TACE. The post procedure analgesic effect was signif-
icant in terms of low pain scores and smaller doses of analgesic
requirement.
In our study Lidocaine was injected after administration of
the chemotherapeutic emulsion and just before embolization
step of TACE by particles.
Lidocaine was administered after chemotherapeutic emul-
sion has partially saturated the vascular bed of the tumor
and embolizing particles have led to the entrapment of Lido-
caine and have prolonged its action.
Superselective embolization is better than lobar TACE as
regards control of non target embolization especially inadver-
tent embolization of the gall bladder which in some theory is
the main cause of pain component of PES (9). In our study
90% of TCAE procedures for HCC lesions were in the right
hepatic lobe (n= 35). Nevertheless we did not have inadver-
tent embolization of gall bladder. Superselective TACE re-
duces the number and length of arteries exposed to irritant
chemotherapeutic emulsion which is one of the theories of pain
component of PES .Superselective TACE is associated with
reduction in the chemotherapeutic dose infused which is an-
other advantage of Superselective over lobar TACE technique
in addition to much better tumor necrosis (16).Lidocaine is metabolized by the liver and its half life is
about 2 and 2 and ½ hours with normal liver functions. Lido-
caine metabolites and unchanged drug are excreted by the kid-
neys. Because of the rapid rate at which Lidocaine is
metabolized, any condition that affects liver function may alter
Lidocaine kinetics. The half-life may be prolonged twofold or
more in patients with liver dysfunction such as cirrhotic patient
with HCC. Entrapment of Lidocaine in the vascular bed of li-
ver tumor that is partially saturated by chemotherapeutic
emulsion and infused embolization particle may prolong the
duration of action Lidocaine but this cannot explain the ex-
tended duration of action for following few days (17).
Intraarterial administration of buffered Lidocaine may al-
ter release of inﬂammatory mediators, for example histamine
release from mast cells in vitro (18), Leukotriene B-4 and Inter-
leukin-1 release from polymorphonuclear granulocytes and
mononuclear cells in vitro, respectively (19). Lidocaine has a
potential anti-inﬂammatory effect (20), however, there is still
a lack of well-designed studies to support this hypothesis.
Interestingly, Kogut et al. (21) found that prophylactic
intraarterial administration of steroids in TACE procedures
did not affect analgesic agent use and had a minor effect on
antiemetic requirements.
In our study, although periprocedure intraarterial Lido-
caine administration improved pain component of PES, the
length of hospital stay was not different in patients who re-
ceived Lidocaine versus patients who received Placebo. This
can be explained by the other component of PES nausea and
vomiting. Our results agreed with those of other authors (22).
The limitation of our study was that the number of patients
and procedures were small. We included patients who had ﬁrst
session of TACE in addition to patients who received previous
TACE session; but sub grouping might affect statistical testing.
In conclusion: Intraarterial administration of buffered
Lidocaine just before infusion of embolization particles in dose
as low as 50 mg is sufﬁcient for pain control during TACE pro-
cedure and helps in pain control after the procedure. Evalua-
tion of TACE inﬂammatory response and the hypothesis
that Lidocaine alters this response can be the topic of further
investigations.
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